Exome Asset Management Dumps Wave Life Sciences Stake Following Volatile First Quarter
Institutional Shift at Wave Life Sciences Exome Asset Management has officially liquidated its entire position in clinical-stage biotechnology firm Wave Life Sciences (NASDAQ: WVE). According to an SEC filing dated May 15, 2026, the fund sold off 421,488 shares, a transaction valued at approximately $5.49 million based on first-quarter average pricing. Prior to the sale, […]










